BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture
Novel pharmaceutical Vicromax(tm)* has already undergone extensive animal testing and human clinical experience in other indications Westport, CT – March 25, 2020 – BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that its majority-owned subsidiary NeuroClear Technologies, Inc. acquired the rights […]
BioSig Completes 100th Patient Case with PURE EP(tm) System
– Commercialization and install plan ahead of schedule – Installations at new centers are driving patient enrollments and clinical data collection Westport, CT – February 19, 2020 — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and […]
BioSig Technologies Signs a New Licensing Agreement with Mayo Clinic
New Agreement to Support Development of Advanced Features of PURE EP(tm) System Westport, CT – September 12, 2019 — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that it signed a new licensing agreement […]
Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors
Santa Monica, CA – May 20, 2019 – BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that Dr. Jerome B. Zeldis agreed to re-join the Company as an Independent Director, effective immediately. Dr. Jerome (“Jerry”) […]
BioSig Technologies Completes Patient Cases at Indiana University
Third Center to Use PURE EP(tm) System Santa Monica, CA – May 06, 2019 – BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company conducted patient cases using the PURE […]
BioSig Completes Successful Patient Cases at Greenville Memorial Hospital
Second Center to Report Positive Clinical Experience with PURE EP(tm) System Santa Monica, CA – April 16, 2019 — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address unmet needs for the electrophysiology (EP) marketplace, today announced that the Company successfully conducted patient cases using PURE EP(tm) […]
BioSig Appoints John Kowalski to Lead Commercialization of PURE EP
Electrophysiology Industry Veteran to Lead Sales Strategy For the Company’s Novel Cardiac Signal Acquisition and Processing Technology Santa Monica, CA, February 4, 2019 — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that […]
Former New Technology Education Manager to Assist with First Installations
Santa Monica, CA, Dec. 19, 2018 — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has appointed Mrs. MaryAnn Edzards as Senior Director – Account Manager.Mrs. Edzards brings […]
BioSig Technologies Signs Agreement with Texas Cardiac Arrhythmia Institute for First–in-Human Studies
Santa Monica, CA, November 27 2018 — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has signed an agreement with Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center in […]
BioSig Technologies Announces New Research Program with Mayo Clinic
New Agreement to Focus on Enhanced Features of PURE EP System and Future Potential Clinical Applications Santa Monica, CA, Nov. 13, 2018 — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today […]
